HIMS

Current Thesis

The GLP-1 pivot trough is in. Q1 2026 (reported ~2026-05-11) was the kitchen-sink quarter — revenue $608M, only +4% YoY, missing the $616-619M estimate, with adj. EBITDA dragged to $44M (7% margin) by ~$33M of restructuring tied to exiting compounded semaglutide in March. But the forward guide reaccelerates hard: Q2 2026 guided to $680-700M (+25-28% YoY), FY raised to $2.8-3.0B (+19-28%). The bridge is the branded Wegovy ramp — 125,000+ shipments in the first 6 weeks, on track for 100k+ new weight-loss subs/month. CFO David Wells bought 48,[position redacted] (~$1.17M) on 2026-05-27. Stock has reclaimed the 50-day at ~$28. Real reacceleration story — but no catalyst until the Aug 10 print, price already sits above every sell-side PT ($23-25), and this is a violently retail-squeeze-coded name. Buy the pullback, don't chase the extension.

Bull Case

• Reaccel guide vs. trough print: Q2 2026 guided $680-700M = +25-28% YoY, a sharp inflection off Q1's +4% ($608M). FY raised to $2.8-3.0B (+19-28%), adj. EBITDA $275-350M. The compounded→branded transition is converting to volume (guidance issued with Q1 print ~2026-05-11).
• Branded Wegovy ramp is fast: 125,000+ Wegovy shipments in the first 6 weeks post-launch; tracking 100k+ new weight-loss subscribers per month (Q1 call, May 2026).
• Insider conviction signal: CFO David Wells bought 48,[position redacted] = ~$1.17M open-market on 2026-05-27 (Form 4). First notable insider buy; now ~15% in the money — a market-respected floor.
• Novo relationship repaired: March 2026 collaboration put the Wegovy pill + branded GLP-1 on the platform (membership $39 first month / $149 after), healing the 2025 partnership blowup that crushed the stock. Removes the legal/supply overhang.
• Tape turning up: +77% off the 2026-02-27 52-week low; reclaimed the 20- and 50-day MAs ([entry redacted]) and the insider cost basis.
• International + ecosystem optionality: generic semaglutide launched in Canada at C$149/mo (2026-05-21); 8 new partners added to the exclusives/benefits program (2026-05-28).

Bear Case

• Q1 2026 missed: $608M rev (+4% YoY) vs. $616-619M est; 7% EBITDA margin gutted by ~$33M restructuring. Growth decelerated to a crawl right before the reaccel promise.
• Guide is a promise, not a print: the +25-28% Q2 reaccel needs the Wegovy ramp to hold; first proof isn't until ~2026-08-10. Until then it's a story stock trading above its targets.
• Sell-side cold and below spot: BofA Neutral, cut PT to $25 (2026-05-26); Truist Hold, PT $23 (2026-05-22). At ~$28 the stock is ABOVE both — no near-term upgrade fuel, downgrade/multiple-compression risk if Q2 stumbles.
• Single-category concentration: weight-loss is now the engine. Any GLP-1 regulatory shift, a Novo re-termination (it happened in 2025), or a pricing war hits the entire thesis at once.
• Competition closing in: CVS reintroduced Zepbound as a covered medication (2026-05-28); Novo/Lilly run their own DTC channels; employer/PBM coverage of branded GLP-1 erodes the cash-pay DTC value prop HIMS monetizes.
• Long-term downtrend intact: still below the 200-day MA (~$34); that level is heavy overhead supply and the multi-month trend hasn't flipped bullish.
• Squeeze-prone, round-trips violently: repeated whale/unusual-options flags (2026-05-25, 2026-06-03). This name can give back 20-30% in a week.

Setup & Price Structure

• Last ~$28 (2026-06-03). Reclaimed 20-day and 50-day MA at $24.31 (bullish short-term). 200-day ~$34 overhead (bearish long-term).
• +77% off the 2026-02-27 52-week low, but still –23% YTD 2026 — a recovery rally inside a longer downtrend, not yet a trend reversal.
• Line in the sand = $24-24.31: confluence of 50-day MA + CFO insider cost basis ([entry redacted]). Hold = structure intact; lose it = thesis broken.
• Above all analyst PTs ($23-25): momentum confirmation, but zero valuation cushion if sentiment turns.
• Entry read: at [entry redacted] with no catalyst for ~9 weeks, the clean add is a pullback into $24-25 (50-day + insider basis), not chasing the extension. Size as a tight probe (a6 → 1%/name cap).

Catalyst Calendar (next 30 days)

• No binary catalyst inside 30 days. Flow/sentiment only:
• ~2026-06 (ongoing): incremental partner/benefit-program expansion headlines (8 partners added 2026-05-28) and GLP-1 coverage news flow (CVS/Zepbound reintroduction 2026-05-28). Sentiment, not numbers.
• ~2026-08-10 (est., OUTSIDE 30d): Q2 2026 earnings — THE binary. Must hit the $680-700M / +25-28% guide. Reaccel thesis is proven or broken here. Earnings blackout applies within 3 trading days.
• No FDA/PDUFA date pending.

What Would Change Our Mind

• Bullish add trigger: pullback to $24-25 holding the 50-day on lighter volume → re-enter/add at the insider basis. Or a clean weekly close back above the 200-day (~$34) reclaiming the long-term trend.
• Hard exit / invalidation: daily close below [entry redacted] (loses 50-day MA + CFO basis) = cut, structure broken. Any Novo Nordisk partnership-termination headline = exit immediately (2025 repeat risk). Q2 (~2026-08-10) revenue <$680M low-end guide = guide credibility gone, exit.
• Trim discipline (a6): RSI > 75 → trim into strength; weekly close below the 20-EMA → trim; RSI > 82 → auto-trim, don't override.
• Theme flip: GLP-1/obesity narrative going SATURATED/DEAD (PBM/employer coverage commoditizes cash-pay DTC; Lilly/Novo direct crush margins) with no replacement thesis → exit.

Correlation Notes

• GLP-1 / obesity complex (LLY, NVO): direct read-through. Novo's Q1 2026 strength (Wegovy pill scripts ~1.3M in Q1, >2M since launch; raised 2026 guidance) is both supply and demand tailwind for HIMS as a distribution channel. Watch Novo prints/guidance as a leading indicator.
• DTC telehealth / digital-health beta (TDOC, GoodRx): moves with growth/retail risk-on; high-beta, retail-flow sensitive.
• Competitive read-throughs: CVS/Zepbound coverage (2026-05-28), Amazon Pharmacy, and employer/PBM GLP-1 coverage are volume/margin threats to the cash-pay model.
• High-beta retail name: amplifies SPY/QQQ risk-on and sells off hard in risk-off. Size and stop accordingly — this is not a low-vol compounder.

Why This Refresh

Prior dossier was mis-tagged "biotech-precision-therapeutics" with no analysis. Corrected: HIMS is a DTC-telehealth / GLP-1-distribution platform. Status moved from DORMANT to an active, MEDIUM-conviction watch — valid reacceleration thesis backed by a real insider buy, but extended off lows, above sell-side PTs, no catalyst for ~9 weeks, and structurally squeeze-prone. Watch the $24 floor; the trade gets interesting on a pullback into the insider basis or on the Aug 10 print.